Van ECK Associates Corp Has $553.29 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Van ECK Associates Corp grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,342,831 shares of the biopharmaceutical company's stock after acquiring an additional 22,847 shares during the quarter. Van ECK Associates Corp owned about 0.51% of Gilead Sciences worth $553,285,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of GILD. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 2.6% during the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company's stock valued at $8,404,161,000 after acquiring an additional 2,910,147 shares during the period. Swedbank AB acquired a new position in shares of Gilead Sciences during the first quarter valued at $134,489,000. International Assets Investment Management LLC boosted its holdings in shares of Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company's stock valued at $137,708,000 after acquiring an additional 1,622,806 shares during the period. Capital Research Global Investors boosted its holdings in shares of Gilead Sciences by 2.7% during the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company's stock valued at $4,486,296,000 after acquiring an additional 1,589,240 shares during the period. Finally, Pacer Advisors Inc. boosted its holdings in shares of Gilead Sciences by 24.7% during the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company's stock valued at $541,310,000 after acquiring an additional 1,564,792 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Up 0.8 %

NASDAQ:GILD traded up $0.69 on Friday, hitting $89.51. 6,485,873 shares of the company's stock traded hands, compared to its average volume of 4,995,384. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $89.74. The firm has a 50-day moving average price of $83.79 and a 200-day moving average price of $74.21. The company has a market cap of $111.44 billion, a PE ratio of 109.16, a price-to-earnings-growth ratio of 3.09 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analysts' expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Equities analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent analyst reports. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $85.00 to $94.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $95.00 to $100.00 and gave the company an "overweight" rating in a research note on Wednesday, October 9th. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an "outperform" rating and a $105.00 price objective on the stock. Evercore ISI upgraded shares of Gilead Sciences to a "strong-buy" rating in a research note on Friday, August 9th. Finally, Barclays lifted their price objective on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an "equal weight" rating in a research note on Monday, October 7th. Ten research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $86.85.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.